Abstract:Congenital disorders of glycosylation (CDG) are a group of rare monogenic human disorders caused by defects in the genes encoding the proteins that generate, attach, and modify glycans, thus disrupting cellular glycosylation machinery. Over 200 CDG caused by disruptions of 189 different genes are currently known. The multi-system disease manifestations of the CDG disorders highlight the importance of glycosylation across the organ systems. Clinical manifestations of CDG tend to group among genes contributing to the same glycosylation pathways, suggesting shared pathophysiology related to the glycosylation disruptions. However, the underlying glycosylation disruptions and pathophysiologic mechanisms responsible for specific CDG clinical manifestations have been determined for only a few hypoglycosylated proteins. The Frontiers in CDG Consortium (FCDGC) is an international network of clinical sites, laboratories, and patient advocacy groups established in 2019 to improve clinical symptoms, quality of life, and life expectancy for individuals with CDG. FCDGC seeks to answer decades of unresolved questions, address knowledge gaps, develop and validate new biochemical diagnostic techniques and therapeutic biomarkers, and explore novel therapeutic options for CDG. Over the past 5 years, FCDGC has launched a Natural History Study with over 300 CDG patients, discovered novel biomarkers suggesting new mechanisms of disease, and launched clinical trials aiming to restore appropriate glycosylation and targeting newly identified potential mechanisms of disease. Technical advances in glycobiology are making it increasingly possible to comprehensively catalog glycoproteomic data and to probe functional impact of altered glycosylation. My laboratory applies glycoproteomic technologies to samples from human subjects and genetic model systems to identify glycosylation abnormalities and unlock new insights from translational glycobiology. Current findings and accomplishments highlight the ongoing bottlenecks and knowledge gaps at intersections of glycobiology and clinical care requiring further investigation.

Sugary Logistics Gone Wrong: Membrane Trafficking and Congenital Disorders of Glycosylation

Congenital Disorders of Glycosylation from a Neurological Perspective

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Biochemical diagnosis of congenital disorders of glycosylation

Congenital Disorders of Glycosylation: What Clinicians Need to Know?

Revisiting the immunopathology of congenital disorders of glycosylation: an updated review

Modeling Congenital Disorders of N-Linked Glycoprotein Glycosylation in Drosophila melanogaster

Congenital Disorders of Glycosylation and Liver Diseases

Serum N-glycan and O-glycan Analysis by Mass Spectrometry for Diagnosis of Congenital Disorders of Glycosylation.

COG8 Deficiency Causes New Congenital Disorder of Glycosylation Type IIh

Hemostatic defects in congenital disorders of glycosylation

Significantly different clinical phenotypes associated with mutations in synthesis and transamidase+remodeling glycosylphosphatidylinositol (GPI)-anchor biosynthesis genes

Genetic counseling for congenital disorders of glycosylation (CDG)

N-Glycosylation as a Modulator of Protein Conformation and Assembly in Disease

Mapping the diagnostic odyssey of congenital disorders of glycosylation (CDG): insights from the community

Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs)

MFSD12 affects glycosphingolipid metabolism by modulating lysosome homeostasis

Metabolism, Cell Surface Organization, and Disease

ALG9-CDG: New Clinical Case and Review of the Literature

Genetics of glycosylation in mammalian development and disease

Insights into molecular and cellular functions of the Golgi calcium/manganese-proton antiporter TMEM165